Celebrating 10 years of innovative, global,
Regulatory solutions & services for Life Sciences industry

Reference Medicinal Products (RMPs) from 1 January 2021

From 1 January 2021 reference medicinal products will have to fall within the definition in regulation 48 of the Human Medicines Regulations 2012. It is our intention to update these Regulations to reflect the change of implementation dates following the Transition Period. Data and market exclusivity period entitlements for reference medicinal products approved before 1 January 2021 will continue to apply in the UK.

This guidance will apply from 1 January 2021 in line with the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019. For Northern Ireland, the definition of a RMP in regulation 48 of the Human Medicines Regulations 2012 should comply with relevant EU legislation. Applicants seeking UK-wide marketing authorisations will be required to comply with requirements applicable in Northern Ireland.

Source: MHRA guideline on Reference Medicinal Products (RMPs) from 1 January 2021

Latest Resources

  • Blogs

    Brexit: The MHRA and The Proposed eSubmission Portal

    Read More
  • White Papers

    Impact of COIVD – 19 on FMCG Supply Chain Regulatory Compliance

    Read More
  • Case Studies

    Expedited Product Classification and NIOSH Certification for N95 Respirator

    Read More

What our Clients Say?

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Quick Inquiry
x